<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:department>Sch of Life Sciences</gtr:department><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BA921764-D144-496F-819B-AC34C67992AA"><gtr:id>BA921764-D144-496F-819B-AC34C67992AA</gtr:id><gtr:firstName>Darren</gtr:firstName><gtr:surname>Thompson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0700850"><gtr:id>7B2FCC36-6F1D-4C82-92DE-D0C8B7F65C35</gtr:id><gtr:title>Structural Studies Of The Complement Component C1</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700850</gtr:grantReference><gtr:abstractText>We aim to look at why certain molecules in the body that normally get rid of invading cells, such as bacteria, suddenly attack our own cells.
The complement system is part of the innate immune system found in man and is made up of over twenty different proteins. The ultimate aim of complement is to bind to the surface of invading bacterial cells, protozoa and tumor cells to create holes in the membrane to kill the target cell. The system is based on a cascade activation so that one protein makes the next protein in the pathway active. 
Although this system serves a protective role it can sometimes inappropriately target self tissues and has been implicated in a wide range of diseases including rheumatoid arthritis, myocardial infarct and Alzheimers disease. 
It is essential to study how these molecules interact with one another and determine if there are any sites on the molecule that would be appropriate for drug intervention. The best way to achieve this is through X-ray crystallography. This technique allows the three dimensional atomic structure of a molecule to be determined. Once the structure of C1 has been determined, its potential as a drug target will be unlocked.</gtr:abstractText><gtr:technicalSummary>The main aim of this project is to elucidate the three dimensional structure of the complement protein C1, using X-ray crystallography. This will enable this molecule to be analysed at the atomic level, which will lead to the identification of sites on the molecule that would be suitable targets for ligand design for possible drug intervention. This can be broken down into the following objectives.

1) We will improve the purification procedure of C1 and analyse the protein for purity, homogeneity and monodispersity.

2) We will deglycosylate the molecule and test for improved homogeneity, monodispersity and crystal growth.

3) We will further refine the crystal growth conditions and cooling techniques so that high resolution, isotropic data may be collected.

4) We will screen the crystals of C1 with heavy atoms to obtain derivatives and collect initial data ?in house? to check on crystal quality and the presence of heavy atoms within the crystal.

5) We will collect data from these derivative crystals using synchrotron radiation.

6) We will process the derivative data sets and determine the position of the heavy atom sites.

7) Using the heavy atom sites, we will phase the data and calculate electron density maps.

8) We will model build the protein into electron density and refine the structure.

9) We will analyse the structure and determine sites for possible drug intervention.

10) We will study C1 using electron microscopy.

11) We will observe the re-assembly of C1 in the presence of a range of ions and at a range of Phs using fluorescence techniques.</gtr:technicalSummary><gtr:fund><gtr:end>2012-04-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-29</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>332292</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">G0700850</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>